You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here Identifier: NCT02654054

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

    Status Completed
    Related Conditions
    Uterine Fibroids
    Heavy Menstrual Bleeding

Enrollment Details

400 Worldwide Enrollment Goal

Study Type:  Interventional

This is a type  phase trial.

Protocol ID

Brief summary


This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Participant Attributes :
  • Female
  • Ages 18 Years to 51 Years

Canada: 1

Ottawa, ON
Would you like to know more about this trial?

Study Design

  • The method used to assign participants to an arm of a clinical trial, for example Randomized (assigned by chance) versus Non-randomized.



  • A target outcome that the study’s protocol aims to evaluate - things like: the occurrence of a disease, a symptom, sign, or lab abnormality, among others.

    Endpoint Classification

    Safety/Efficacy Study

  • The general design that shows how the medical interventions will be assigned to the participants, e.g., whether all patients will receive the same drug, or if different groups receive two or more different treatments in a particular order.

    Intervention Model

    Parallel Assignment

  • The general design that describes the strategy for identifying and following up with participants during observational studies.


    Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

  • This is the single main reason for carrying out the clinical trial. Reasons can include: treatment, prevention, diagnostic advances, supportive care, screening, or health services research, among others.



    • Subject is a premenopausal female at the time of Screening.
    • Subject has a diagnosis of uterine fibroids documented by a Pelvic Ultrasound (TAU, TVU).
    • Subject has HMB associated with uterine fibroids as evidenced by MBL > 80 mL during each of two screening menses as measured by the alkaline hematin method.
    • Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.
    • Subject has an adequate endometrial biopsy performed during Screening, the results of which show no clinically significant endometrial pathology.
    • Subject has screening pelvic ultrasound or SIS results that show a clinically significant gynecological disorder.
    • Subject has history of osteoporosis or other metabolic bone disease.
    • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.
    • Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).
    • Subject is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

More on this trial